Why the study?
Does enoxaparin 40 mg subcutaneously per day reduce the risk of venous thromboembolism in patients with acute medical illnesses compared to placebo?
Does enoxaparin 40 mg subcutaneously per day reduce the risk of venous thromboembolism in patients with acute medical illnesses compared to placebo?
Enoxaparin 40 mg daily is safe and effective for VTE prophylaxis in acutely ill medical patients.
No takes yet. Share an insight, caveat, or question.
Supports enoxaparin 40 mg daily for VTE prophylaxis in acute medical illness; confirms LMWH efficacy versus placebo in this population.
Samama et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: